833 completed, 231 unknown, 113 terminated, 95 recruiting. 1428 Phase 3, 235 Phase 2.
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial Umbilical cord Mesenchymal stem cell, Steroid, Standard Medical Treatment - Acute-On-Chronic Liver Failure | Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2028-01-01 | 2025-08-17 |
| Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic | Phase 3 | Not yet recruiting | Shanghai HEP Pharmaceutical Co., Ltd. | 150 | 2027-06-01 | 2026-10-28 |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) - Hepatocellular Carcinoma (HCC) | Phase 3 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-12-01 | 2026-10-26 |
| Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni | Phase 2 / Phase 3 | Not yet recruiting | Rhode Island Hospital | 600 | 2026-11-01 | 2026-08-12 |
| A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 690 | 2026-11-01 | 2026-10-29 |
| Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients Placebo, Roflumilast - NAFLD (Nonalcoholic Fatty Liver Disease) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 60 | 2026-11-01 | 2026-10-28 |
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1500 | 2026-10-28 | 2026-11-05 |
| Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients. Placebo, Rupatadin - NAFLD (Nonalcoholic Fatty Liver Disease) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 60 | 2026-10-25 | 2026-10-28 |
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Recruiting | BeOne Medicines | 492 | 2026-10-23 | 2026-11-10 |
| Study of BK1803 in Healthy Infants BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Recruiting | Tanabe Pharma Corporation | 344 | 2026-10-21 | 2026-11-12 |
| J-LINX: Japan LINerixibat eXtension Study Linerixibat - Pruritus | Phase 3 | Not yet recruiting | GlaxoSmithKline | 40 | 2026-10-09 | 2026-10-06 |
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
| Study Interchangeability Hep-B Vaccine Administered at Birth Dose In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine - Vaccination Adverse Event, Immunogenicity, Vaccine | Phase 3 | Not yet recruiting | PT Bio Farma | 270 | 2026-10-01 | 2026-10-02 |
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| Misocholic Tablets for Non-Viral Elevated Liver Enzymes Misocholic Tab, Placebo, Silymarin (Silybum marianum) - Alcohol-Related Liver Disease, Drug-Induced Liver Injury | Phase 3 | Not yet recruiting | Hanoi Medical University | 60 | 2026-09-15 | 2026-09-22 |
| Efficacy of Diloxanide Furoate as Additional Luminal Agent Along With Metronidazole for the Treatment of Amoebic Liver Abscess Diloxanide furoate, Placebo - Liver Abscess, Amoebic Liver Abscess | Phase 3 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 220 | 2026-09-04 | 2026-09-10 |
| Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. TETA 4HCl formulation, D-Penicillamine - Wilson's Disease | Phase 3 | Recruiting | Orphalan | 38 | 2026-09-03 | 2026-10-15 |
| ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 600 | 2026-09-01 | 2026-09-10 |
| A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP) PORT-77, Placebo - Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Phase 2 / Phase 3 | Recruiting | Portal Therapeutics, Inc. | 225 | 2026-09-01 | 2026-09-15 |
Showing 20 of 1428. Sign in to see all of them.
Carcinoma, Hepatocellular (317) · Hepatitis C (284) · Hepatitis C, Chronic (201) · Hepatitis B (195) · Liver Cirrhosis (98) · Fibrosis (95) · Liver Neoplasms (91) · Non-alcoholic Fatty Liver Disease (90) · Hepatitis B, Chronic (85) · Diphtheria (57) · Tetanus (56) · Hepatitis (52) · Haemophilus Infections (47) · Liver Cirrhosis, Biliary (44)
Digestive System Diseases (1413) · Infections (687) · Hepatitis (672) · Hepatitis, Viral, Human (668) · Virus Diseases (667) · Blood-Borne Infections (651) · Communicable Diseases (648) · Pathological Conditions, Signs and Symptoms (571) · Pathologic Processes (547) · RNA Virus Infections (475) · Flaviviridae Infections (389) · Neoplasms by Site (357) · Digestive System Neoplasms (354) · Neoplasms (345)
Ribavirin (202) · peginterferon alfa-2a (104) · peginterferon alfa-2b (62) · Sorafenib (51) · Sofosbuvir (49) · Tenofovir (39) · daclatasvir (32) · ombitasvir (32) · paritaprevir (30) · glecaprevir and pibrentasvir (28) · lenvatinib (28) · dasabuvir (27) · entecavir (26) · Hepatitis B Vaccines (25) · telaprevir (23)
GlaxoSmithKline (75) · Merck Sharp & Dohme LLC (66) · Gilead Sciences (60) · Sun Yat-sen University (51) · AbbVie (49) · Bristol-Myers Squibb (46) · Sanofi Pasteur, a Sanofi Company (25) · Hoffmann-La Roche (23) · Guangxi Medical University (22) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (16) · Tanta University (14) · Novartis Pharmaceuticals (13) · Boehringer Ingelheim (12) · French National Agency for Research on AIDS and Viral Hepatitis (11) · Shanghai Zhongshan Hospital (11)
United States (392) · China (298) · France (231) · Canada (215) · Germany (203) · Spain (194) · Italy (186) · United Kingdom (184) · Australia (149) · South Korea (148) · Belgium (141) · Taiwan (125) · Poland (120) · Puerto Rico (97) · Japan (94)
Ming Shi, MD (12)
PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 29377566, PMID 29404492, PMID 12049862, PMID 28193518, PMID 11981766, PMID 25040192, PMID 25583164, PMID 27847279, PMID 30868245, PMID 35174470, PMID 37467180, PMID 37771546, PMID 37786277, PMID 12540794, PMID 19192962, PMID 21836029, PMID 25445400, PMID 26743093, PMID 26947564, PMID 27553375, PMID 32557715, PMID 36633470, PMID 36740893, PMID 37143199, PMID 37302573, PMID 40434633, PMID 40704461, PMID 10207464, PMID 12091661, PMID 16026887, PMID 17716936, PMID 18650514, PMID 19052126, PMID 19553649, PMID 20189674, PMID 20955704, PMID 22030902, PMID 22239511, PMID 22338037, PMID 22626609, PMID 23234725, PMID 23364953, PMID 23607593, PMID 23607594
2015 (25), 2014 (24), 2016 (16), 2023 (13), 2019 (10), 2004 (8), 2025 (8), 2008 (7), 2009 (7), 2017 (7), 2005 (5), 2018 (5), U01DK082843 (3), U01DK082864 (3), U01DK082871 (3)